|
|
News Breaks | | | | January 22, 2013 | | 10:00 EDT |  | GALT | Galectin Therapeutics rises 14.3%
Galectin Therapeutics is up 14.3%, or 33c, to $2.64 | |
|
News For GALT From The Last 14 Days Check below for free stories on GALT the last two weeks. |
|
|
| June 12, 2013 | | 08:04 EDT |  | GALT | Galectin Therapeutics announces positive results from GR-MD-02 study
Galectin Therapeutics announced that preclinical studies have shown that combining the galectin inhibitor GR-MD-02 with monoclonal antibodies that function as immune checkpoint blockade inhibitors enhance shrinkage of prostate and breast cancer tumors. he addition of GR-MD-02, a drug that inhibits galectin proteins, was found to increase tumor shrinkage and enhance survival in immune competent mice with prostate and breast cancers when combined with one of the immune checkpoint blockade inhibitors, anti-CTLA-4 or anti-PD-1. | |
|
|
|
|
|
|
